ArriVent Pushes Dual-Target Ovarian Cancer Drug Into Trials
NEWTOWN SQUARE, PA — ArriVent BioPharma (Nasdaq: AVBP) received U.S. Food and Drug Administration clearance to begin human testing of an experimental antibody-drug conjugate designed to improve targeting of ovarian …
ArriVent Pushes Dual-Target Ovarian Cancer Drug Into Trials Read More